Search
Now showing items 1-10 of 24
Treating the ineligible: Disease modification in people with multiple sclerosis beyond NHS England commissioning policies.
(Elsevier/Science Direct, 2018-11-02)
BACKGROUND: Whilst there is a broad selection of drugs licensed as disease modifying treatments (DMTs) for people with relapsing multiple sclerosis (pwRMS), access to DMTs remains restricted, particularly for people with ...
Alemtuzumab depletion failure can occur in multiple sclerosis.
(2018-06)
Alemtuzumab is a lymphocyte-depleting antibody and one of the most effective treatments for relapsing multiple sclerosis. However, it also causes loss of immune-tolerance leading to secondary autoimmunity and marked anti-drug ...
Validation of an environmentally-friendly and affordable cardboard 9-hole peg test.
(2017-10)
BACKGROUND: In multiple sclerosis (MS) upper limb neurological impairments, are an important driver of disability and handicap. The gold standard for assessing upper limb function is the 9-hole peg test (9HPT). One ...
Cladribine Personalised Dosing to Treat Active Multiple Sclerosis - Follow-up in 250 patients
(2021-06)
This is the accepted manuscript of an article published online:
1. ACTRIMS Forum 2021 – Poster Presentations. Multiple Sclerosis Journal. 2021;27(1_suppl):15-122. doi:10.1177/13524585211015908